This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
This was a diagnostic study that was carried out in a single institution in New Delhi, India. A single group of patients underwent both diagnostic evaluations. Each patient was subjected to thoracocentesis and pleural fluid was analysed. Whenever lesser invasive means failed to yield the diagnosis, the patients were subjected to pleural biopsy. Ultrasonography and computed tomography of the chest, wherever indicated, were performed to establish the etiology of pleural effusion. The criteria used to make a diagnosis of TB pleural effusion were reported. Those patients with TB were followed up to evaluate the response to anti-tuberculosis treatment (ATT). All patients showed clinical as well as radiological response to ATT. No patient was lost to follow-up.
Analysis of effectiveness
All of the patients included in the initial study sample were accounted for in the analysis of effectiveness. The outcome measures used were: pleural fluid levels among patients in the TB and the non-TB groups; the sensitivity and specificity; and the numbers of true-negative, true-positive, false-negative and false-positive cases.
In addition, sensitivity and specificity were plotted for various cut-off levels for pleural fluid IFN-gamma and ADA in order to construct the receiver-operator characteristics (ROC) curve. The area under the ROC curve (AUC) was assessed to compare the diagnostic utility of IFN-gamma levels with ADA for the diagnosis of TB pleural effusion.
Effectiveness results
The median levels of pleural fluid assessed using IFN-gamma were significantly higher among TB patients (2,100 pg/mL; range: 70 -14,000) than among non-TB patients (3 pg/mL; range: 0 -160).
Similarly, the mean levels of pleural fluid assessed using ADA were significantly higher among TB patients (93.1 +/-62.3 IU/L) than among non-TB patients (15.4 +/-8.7 IU/L). ROC curves were plotted. These showed that both IFN-gamma and ADA had high AUC values, although IFN-gamma was marginally superior to ADA, 0.997 (95% confidence interval, CI: 0.988 -1.006) versus 0.963 (95% CI: 0.915 -1.011). The best cut-off was 167.5 pg/mL for IFN-gamma and 33 IU/L for ADA.
The best cut-off for IFN-gamma resulted in a sensitivity of 97.1% for diagnosis of TB pleural effusion, and a negative predictive value of 94.4%. The specificity and positive predictive value were both 100%.
The best cut-off for ADA resulted in a sensitivity of 91.4% and a negative predictive value of 85%. However, both the specificity and positive predictive value were 100%.
There were 17 true-negative cases with both techniques, 34 true positives with IFN-gamma and 32 with ADA, 1 false negative with IFN-gamma and 3 with ADA, and 0 false-positive cases with either tool. Thus, ADA missed diagnosis in 5.7% more patients (2) than what was missed by IFN-gamma estimation. Hence, 17.5 IFN-gamma estimations needed to be performed to diagnose one patient falsely labelled negative on the basis of the ADA estimation.
Clinical conclusions
The effectiveness analysis showed that the diagnostic accuracy of ADA was slightly lower than that of IFN-gamma.
Measure of benefits used in the economic analysis
The health outcomes were left disaggregated and no summary benefit measure was used in the economic evaluation. In effect, a cost-consequences analysis was performed.
